Data gathered: July 11
Alternative Data for Exelixis
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 45 | Sign up | Sign up | Sign up |
| Sentiment | 96 | Sign up | Sign up | Sign up |
| Webpage traffic | 42,000 | Sign up | Sign up | Sign up |
| Employee Rating | 42 | Sign up | Sign up | Sign up |
| Google Trends | 12 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 12 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 12,189 | Sign up | Sign up | Sign up |
| Twitter Followers | 5,658 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 7 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,489 | Sign up | Sign up | Sign up |
About Exelixis
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
| Price | $44.86 |
| Target Price | Sign up |
| Volume | 1,970,000 |
| Market Cap | $12.3B |
| Year Range | $32.38 - $46.26 |
| Dividend Yield | 0% |
| PE Ratio | 20.63 |
| Analyst Rating | 60% buy |
| Industry | Biotechnology |
In the news
 |
Bank of New York Mellon Corp Grows Position in Exelixis, Inc. (NASDAQ:EXEL)July 11 - ETF Daily News |
 |
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-TermJuly 9 - Yahoo |
|
Principal Financial Group Inc. Sells 14,218 Shares of Exelixis, Inc. (NASDAQ:EXEL)July 9 - ETF Daily News |
|
Traders Buy Large Volume of Call Options on Exelixis (NASDAQ:EXEL)July 8 - ETF Daily News |
 |
Exelixis: I Was Wrong To Be Too Cautious (Rating Upgrade)July 7 - SeekingAlpha |
|
Why Exelixis (EXEL) is a Top Growth Stock for the Long-TermJuly 6 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 555M | 19M | 536M | 160M | 194M | 0.620 |
| Q4 '24 | 567M | 20M | 547M | 140M | 171M | 0.550 |
| Q3 '24 | 540M | 17M | 522M | 118M | 195M | 0.400 |
| Q2 '24 | 637M | 18M | 620M | 226M | 284M | 0.770 |
| Q1 '24 | 425M | 21M | 404M | 37M | 69M | 0.200 |
Insider Transactions View All
| WYSZOMIERSKI JACK L filed to sell 358,882 shares at $43.1. June 4 '25 |
| Eckhardt Sue Gail filed to sell 21,380 shares at $43.7. June 4 '25 |
| Eckhardt Sue Gail filed to sell 21,384 shares at $42.7. June 4 '25 |
| Heyman Tomas J. filed to sell 32,470 shares at $44.3. May 22 '25 |
| Haley Patrick J. filed to sell 412,072 shares at $44.1. May 22 '25 |
Similar companies
Read more about Exelixis (EXEL) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Exelixis?
The Market Cap of Exelixis is $12.3B.
What is Exelixis' PE Ratio?
As of today, Exelixis' PE (Price to Earnings) ratio is 20.63.
What is the current stock price of Exelixis?
Currently, the price of one share of Exelixis stock is $44.86.
How can I analyze the EXEL stock price chart for investment decisions?
The EXEL stock price chart above provides a comprehensive visual representation of Exelixis' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Exelixis shares. Our platform offers an up-to-date EXEL stock price chart, along with technical data analysis and alternative data insights.
Does EXEL offer dividends to its shareholders?
As of our latest update, Exelixis (EXEL) does not offer dividends to its shareholders. Investors interested in Exelixis should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Exelixis?
Some of the similar stocks of Exelixis are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.